Patrick M Forde

30PUBLICATIONS
310CO-AUTHORS
Predictive and prognostic markersCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 23, 2026
Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.

|Jul 01, 2026
Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical EGFR Mutation: A Molecular Tumor Board Discussion.

|Apr 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

|Apr 19, 2026
plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.

|Mar 18, 2026
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability.

M Raheel Khan, Patrick M Forde

|Sep 08, 2025
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.

Joshua E Reuss, Paul K Lee, Reza J Mehran

Pageof 5

Frequent Collaborators

17 joint publications

Valsamo Anagnostou

8 joint publications

Kellie N Smith

8 joint publications

Joseph Murray

7 joint publications

Julie R Brahmer